Bourdage to Retire as BASi VP of Bioanalytical Operations
James Bourdage
Subscriber Benefit
As a subscriber you can listen to articles at work, in the car, or while you work out. Subscribe NowWest Lafayette-based Bioanalytical Systems Inc. has announced James Bourdage (pictured) is retiring. He is vice president of bioanalytical operations. Michael Baim will succeed Bourdage effective May 7.
Before joining the company nearly four years ago, Bourdage spent his career in the pharmaceutical industry. Having received his Ph.D. in immunochemistry from the University of Illinois, he served in leadership positions at Covance, PharmAthene, Eli Lilly and Pharmacia/Upjohn. In addition to authoring numerous scientific papers, Bourdage is a member of the American Society of Clinical Pathologists and the American Association of Pharmaceutical Scientists.
Baim has more than 30 years of experience in the pharmaceutical and lab management industries. He is well-versed in analytical methodology and project design and has a proven track record of delivering significant and sustainable profitable growth across many different business segments.
Baim received his B.A. degree in chemistry from Whitman College in Washington State. He then studied analytical chemistry as an American Chemical Society Analytical Research Fellow at Washington State University, where he earned his Ph.D. degree. He is currently working towards his MBA in marketing management.
Baim began his career at The Procter & Gamble Company in 1984, and has since held several leadership, management and technical positions at other prominent companies including Novartis and Bristol-Myers Squibb/Mead Johnson. Most recently, he served as an analytical laboratory director, designing a new analytical chemistry lab and revitalizing chemistry operations by adding new technologies and staff to optimize technical guidance and improve customer service. These efforts resulted in a sustained, double-digit growth rate for the company.